NASDAQ:CADL Candel Therapeutics Q2 2026 Earnings Report $10.84 -0.51 (-4.45%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$10.84 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Candel Therapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.24Beat/MissMissed by -$0.28One Year Ago EPSN/ACandel Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACandel Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:00AM ETUpcoming EarningsCandel Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Candel Therapeutics Earnings HeadlinesCandel Therapeutics, Inc. (NASDAQ:CADL) Receives $19.29 Consensus Target Price from AnalystsSeptember 14, 2026 | americanbankingnews.comCandel Therapeutics Adds Regulatory Executive Martine Zimmermann To Board As BLA Filing NearsSeptember 11, 2026 | rttnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 19 at 1:00 AM | InvestorPlace (Ad)Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of DirectorsSeptember 10, 2026 | globenewswire.comCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comShow Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing NearsAugust 28, 2026 | rttnews.comSee More Candel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email. Email Address About Candel TherapeuticsCandel Therapeutics (NASDAQ:CADL) is a clinical-stage biotechnology company developing multimodal biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company focuses on engineered viruses administered directly into tumors, with the goal of creating a localized immune response that may also affect cancer cells elsewhere in the body. Candel’s pipeline includes CAN-2409, an investigational, replication-defective adenovirus-based immunotherapy being studied in cancers including localized prostate cancer and non-small cell lung cancer. The company is also developing CAN-3110, an investigational oncolytic herpes simplex virus intended for the treatment of recurrent glioblastoma. These programs are supported by Candel’s enLIGHTEN discovery platform, which is designed to generate and evaluate novel viral immunotherapies. Founded in 2015 and headquartered in Needham, Massachusetts, Candel conducts its research and clinical development activities primarily in the United States. The company’s products remain investigational and are not approved for commercial use. Candel is led by President and Chief Executive Officer Paul Peter Tak, M.D., Ph.D.View Candel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
